Victoria Socha

DocwireNews

Immunomodulator cotherapy has been shown to improve the efficacy of pegloticase by reducing its immunogenicity. Results of the PROTECT study, an open-label, single-arm study in kidney transplant recipients on stable immunosuppressants with uncontrolled gout suggested that pegloticase was effective in reducing serum urate levels, with a high responder rate of 89% (serum urate &lt;6 mg/dL for &ge;80% of the time during month 6, while preserving key indicators of graft function).Abdul A. Abdellatif, MD, and colleagues conducted a study to assess the pharmacokinetics and immunogenicity of pegloticase in patients with uncontrolled gout with a history of kidney transplant on immunosuppression. Results were reported during a poster session at the American Society of Nephrology Kidney Week 2022 in a poster titled Pharmacokinetics and Immunogenicity of Pegloticase in Patients With Kidney Transplants Revoicing Pegloticase for Uncontrolled Gout.Pegloticase was administered via intravenous (IV) infusion 8 mg every 2 weeks for 24 weeks. Pharmacokinetics and immunogenicity analyses were conducted using serum samples collected pre- and postdose at multiple visits.The analysis included 20 patients who received at least one dose of pegloticase. Among serum urate responders, measurable pegloticase concentrations were maintained through month 6. Following initiation of pegloticase treatment, median pre- and postdose pegloticase concentration ranged from 0.97 to 1.59 &micro;g/mL and 1.57 to 3.60 &micro;g/mL, respectively. Conversely, the two nonresponders both had predose concentrations of pegloticase below the limit of quantification (BLQ), and one had a BLQ value postinfusion, consistent with the immunogenicity results.Pegloticase exposures were higher in patients observed with pegloticase monotherapy, consistent with previously observed improved pharmacokinetic seen with methotrexate cotherapy. There were no reactions or anaphylaxis during the trial period.&ldquo;Pegloticase 8 mg IV every 2 weeks with standard of care immunosuppressants in transplant patients resulted in a high serum urate responder rate and improved pegloticase exposure,&rdquo; the researchers said.Source: Abdellatif AA, Xin Y, Chamberlain J, et al. Pharmacokinetics and immunogenicity of pegloticase in patients with kidney transplants receiving pegloticase for uncontrolled gout. FR-PO232. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2022; November 4, 2022; Orlando, Florida.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Treating Gout in Kidney Transplant Recipients on Immunosuppression

ASN Kidney Week 2022

Immunomodulator cotherapy has been shown to improve the efficacy of pegloticase by reducing its immunogenicity. Results of the PROTECT study, an open-label, single-arm study ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe